evernorth glp-1 Evernorth reaches deals with Novo Nordisk, Eli Lilly to cap GLP-1 copays GLP-1s: Impact on Health Costs
Description
The company plans more than 20 anti-obesity trials, including 10 Phase 3 studies targeted for 2026, as it builds out its obesity franchise
These drugs work by mimicking a gut hormone that slows digestion and reduces appetite, leading to significant weight loss in many patients
Dozens of low cost versions are pressuring pricing for obesity and diabetes drugs, prompting Novo Nordisk to lower prices on its own GLP-1 brands
Should Medicare and Medicaid expand to cover weight loss drugs
GLP-1 patches for weight loss have made the scenebut a leading MD warns you they aren't the same as the more familiar prescriptions.
